Of the limited number of larger prospective trials, PD-1 and PD-L1 blockade have often been incorporated into standard dosing regimens of SBRT and chemoradiation routinely used in the treatment of locally advanced pancreatic cancer and NSCLC, for example (Table 3). This evidence concerns the gene PDCD1 and pancreatic neoplasm.